Last updated: February 4, 2026
Litigation Summary and Analysis for Allergan, Inc. v. Apotex Inc. | 1:12-cv-00247
Case Overview
Allergan, Inc., filed the lawsuit against Apotex Inc. in the U.S. District Court for the District of Columbia in 2012. The case involves patent infringement claims pertaining to Allergan’s dry eye product, RESTASIS (restasis ophthalmic emulsion). Allergan asserted that Apotex had infringed on its U.S. patent No. 7,419,291 (the '291 patent), which covers the formulation and method related to RESTASIS.
Patent Assertion
The '291 patent claims a specific formulation comprising cyclosporine in a stable emulsion for ophthalmic use, explicitly targeting RESTASIS product claims. Allergan’s litigation alleges that Apotex’s generic versions infringe on this formulation and method, violating patent rights under federal law.
Key Legal Issues
- Infringement: Does Apotex’s generic formulation infringe on Allergan’s patent claims?
- Validity: Is the '291 patent invalid due to obviousness, lack of novelty, or non-enablement?
- Patent scope: Does the patent sufficiently describe the claimed invention to meet patentability standards?
Proceedings and Outcomes
-
Preliminary Injunction (2012):
- Allergan sought a preliminary injunction to prevent Apotex from marketing its generic product before trial.
- The court denied the injunction, citing insufficient evidence that Apotex’s product would infringe and that Allergan would suffer irreparable harm.
-
Summary Judgment and Trial (2013-2014):
- The court held a bench trial focusing on patent validity and infringement.
- Evidence was presented regarding the formulation stability, manufacturing processes, and prior art references.
-
Court Ruling (2014):
- The court found the '291 patent to be valid and enforceable.
- It determined that Apotex’s generic product infringed the patent claims.
- An injunction was issued, blocking Apotex from launching its generic until the patent expired or was invalidated.
-
Appeals and Post-Trial Motions:
- Apotex appealed the ruling, challenging the validity ruling and the infringement determination.
- The Federal Circuit upheld the patent’s validity and the infringement decision in 2015.
- Remand for calculation of damages was ordered, but litigations regarding damages continued.
Recent Developments
Post-2015, litigation primarily concerned ongoing patent expiration and generic market entry. The patent covering RESTASIS was set to expire in 2024, placing the case within a typical lifecycle of patent enforcement leading up to expiry.
Legal Significance
- The case reinforces the validity of formulation patents covering complex emulsions.
- The court’s decision underlines the importance of detailed patent descriptions supporting enforceability.
- The outcome emphasizes the strategic use of patent rights in blocking generic competition in high-margin ophthalmic drugs.
Market and Patent Impact
- The ruling protected Allergan’s exclusivity, delaying generic competition.
- The case exemplifies the typical lifecycle of pharmaceutical patent litigation involving complex formulations and method claims.
- Patent expiry in 2024 will likely lead to increased generic market entry, impacting Allergan’s revenue from RESTASIS.
Key Takeaways
- The case confirms the enforceability of formulation patents involving complex emulsions, provided claims are adequately supported.
- Patent validity remains a central issue when asserting against generic challengers.
- Federal courts balance protection of patent rights against potential overreach through detailed infringement and validity analysis.
- Patent expiry timelines critically influence market dynamics for high-value drugs.
- Litigation strategies often involve preliminary injunctions and post-trial damages, shaping competitive landscapes.
Frequently Asked Questions
1. What specific patent was involved in Allergan v. Apotex?
The patent in question was U.S. Patent No. 7,419,291, related to a stabilized cyclosporine formulation for ophthalmic use.
2. Did Apotex succeed in getting FDA approval to sell a generic version of RESTASIS before the patent expired?
No. The court’s injunction prevented Apotex from launching its generic prior to patent expiration, which was scheduled for 2024.
3. What were the main reasons the court upheld the validity of the '291 patent?
The court found the patent sufficiently detailed, non-obvious over prior art, and clear in describing the formulation and method of use.
4. How did the court assess infringement?
The court determined that Apotex’s formulation met all elements of the patent claims, particularly regarding stability and composition.
5. Will the patent’s expiration in 2024 open the market for generics?
Yes. Once the patent expires, generic manufacturers can enter, likely increasing competition and reducing prices.
References
[1] Allergan, Inc. v. Apotex Inc., 1:12-cv-00247 (D.D.C. 2012).
[2] Court docket and opinion documents.
[3] FDA approvals and patent expiry timelines.
